Table of Content

1. Service Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. France Cell Therapy Manufacturing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
5.2.2. By Source of Cell (Autologous, Allogenic)
5.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
5.2.4. By Source (In-House, Contract Manufacturing)
5.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
5.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
5.2.7. By Region
5.2.8. By Company (2022)
5.3. Market Map
5.3.1. By Therapy
5.3.2. By Source of Cell
5.3.3. By Scale of Operation
5.3.4. By Source
5.3.5. By Application
5.3.6. By End User
5.3.7. By Region
6. Northern France Cell Therapy Manufacturing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
6.2.2. By Source of Cell (Autologous, Allogenic)
6.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
6.2.4. By Source (In-House, Contract Manufacturing)
6.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
6.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
7. Southern France Cell Therapy Manufacturing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
7.2.2. By Source of Cell (Autologous, Allogenic)
7.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
7.2.4. By Source (In-House, Contract Manufacturing)
7.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
7.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
8. Western France Cell Therapy Manufacturing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
8.2.2. By Source of Cell (Autologous, Allogenic)
8.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
8.2.4. By Source (In-House, Contract Manufacturing)
8.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
8.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
9. Central France Cell Therapy Manufacturing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
9.2.2. By Source of Cell (Autologous, Allogenic)
9.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
9.2.4. By Source (In-House, Contract Manufacturing)
9.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
9.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
10. Eastern France Cell Therapy Manufacturing Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
10.2.2. By Source of Cell (Autologous, Allogenic)
10.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
10.2.4. By Source (In-House, Contract Manufacturing)
10.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
10.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
11. Southwestern France Cell Therapy Manufacturing Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
11.2.2. By Source of Cell (Autologous, Allogenic)
11.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
11.2.4. By Source (In-House, Contract Manufacturing)
11.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
11.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Developments
13.2. Mergers & Acquisitions
13.3. Product Launches
14. Policy & Regulatory Landscape
15. Porter’s Five Forces Analysis
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. France Economic Profile
17. Competitive Landscape
17.1. Business Overview
17.2. Product Offerings
17.3. Recent Developments
17.4. Financials (As Reported)
17.5. Key Personnel
17.6. SWOT Analysis
17.6.1. Novartis AG
17.6.2. Roche SAS
17.6.3. Gilead Sciences, Inc
17.6.4. Catalent, Inc
17.6.5. Cell and Gene Therapy Catapult
17.6.6. Merck KGaA
17.6.7. Lonza France
17.6.8. Charles River Laboratories
17.6.9. Institut Merieux (ABL Inc.)
17.6.10. Amgen
18. Strategic Recommendations